Corporate Presentation August 2024 NYSE: CATX

Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this presentation include statements concerning, among other things, the Company's clinical development plans and the expected timing thereof; the expected timing for availability and release of data; the Company’s timing and expectations regarding regulatory communications, submissions and approvals; expectations regarding the potential market opportunities for the Company’s product candidates; the Company’s expected cash runway; the potential functionality, capabilities and benefits of the Company’s product candidates; the potential size of the commercial market for the Company’s product candidates; the Company’s expectations, beliefs, intentions, and strategies regarding the future; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the potential that regulatory authorities may not grant or may delay approval for the Company’s product candidates; uncertainties and delays relating to the design, enrollment, completion and results of clinical trials; unanticipated costs and expenses; early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of regulatory authorities may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company may not be able to maintain regulatory approval for the Company’s product candidates; delays, interruptions or failures in the manufacture and supply of the Company’s product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its clinical development programs; the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of its product candidates; the ability of the Company to manage growth; whether the Company can maintain its key employees; whether there is sufficient training and use of the Company’s products and product candidates; the market acceptance and recognition of the Company’s products and product candidates; the Company’s ability to maintain and enforce its intellectual property rights; whether the Company can maintain its therapeutic isotope supply agreement with the DOE; whether the Company will continue to comply with the procedures and regulatory requirements mandated by the FDA for additional trials, Phase 1 and 2 approvals, Fast Track approvals, and 510(k) approval and reimbursement codes; and any changes in applicable laws and regulations. Other factors that may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and the Company’s most recent Quarterly Report on Form 10-Q, each filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this presentation are made as of this date, and the Company undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

Platform radiopharmaceutical company targeting pan-cancer opportunities utilizing 2nd generation ⍺-emitter Robust clinical pipeline with three clinical-stage programs. VMT-⍺-NET for neuroendocrine tumors; VMT01 for melanoma; PSV359 for multiple solid tumors  Multiple expected near-term readouts and milestones through to 2025 Proprietary chelator-based peptide targeting platform provides engine for pipeline expansion Theranostic 203Pb – 212Pb dual isotope enables imaging and therapy, improving patient selection and outcomes Vertically integrated in-house manufacturing of 212Pb isotope simplifies manufacturing and can leverage existing radiopharmacy logistics for broad distribution Investment Highlights

Funding into mid-2026 Strong Financial Position Cash, cash equivalents and short-term investments as of June 30, 2024 $292.9 million Share count as of June 30, 2024 67.4 million Outstanding common stock warrants & options as of June 30, 2024 7.4 million Outstanding pre-funded warrants as of June 30, 2024 3.2 million Based on Perspective’s current plans, which include advancing current clinical programs based on readout, progressing multiple pre-IND assets towards clinical trials, as well as acquiring and developing several regional manufacturing sites, the Company expects to have sufficient funding into mid-2026.

Platform Expansion EngineThree Lead Programs in Clinic and Broad Proprietary Pipeline Program Tumor Type Discovery Human Clinical Imaging First in Human Therapy Phase 1/2 Phase 3 VMT-⍺-NET Neuroendocrine cancers       Pheochromocytomas, paragangliomas       Small cell lung cancer       VMT01/02 Melanoma (MC1R imaging & therapy)       PSV359 (Novel peptide) Multiple (FAP imaging & therapy)     PSV40X (Radio-hybrid) Prostate (PSMA imaging & therapy)   Program 5 (Novel peptide) Prostate, Breast   Pre-targeting Platform (mAbs) Solid and hematological tumors Other Programs (Novel peptides) Solid and hematological tumors  

1 Investigator led research in India in patients with neuroendocrine tumor and medullary thyroid carcinomas. 2 RP2D = recommended Phase 2 dose; ICI = immune check point inhibitor. Program Target Tumor Types Nominate Candidate IND Filing Initiate Cohort 1 Enrolled Cohort 2 Preliminary Update RP2D2 Status Key future milestones & expected timelines VMT-α-NET SSTR2 Neuro-endocrine Tumors      Update to timing expected late 2024 Cohorts 1&2 Initial results: 2H 2024 Duration of results: 2025 Cohort 3: Pending FDA interaction VMT01/ VMT02 MC1R Metastatic Melanoma     Expected 2H 2024 ICI combo study with nivolumab results expected 2025 Cohorts 1&2 Initial results: 2H 2024 Duration of results: 2025 Combination cohorts Initial dosing: 2H 2024 Initial results: 2025 PSV359 FAP-α Multiple solid tumors  Expected late 2024 Expected 2025 Various Discovery Programs PSMA Prostate Expected late 2024 Undisclosed Breast Undisclosed Lung (Investigator led research1) Delivering Momentum Across Solid Tumor ProgramsPlatform for consistent generation and development of new assets

Michael Schultz, PHDChief Science Officer 20+ years industry and research experience in radiopharmaceuticals; co-founder Viewpoint MT & inventor of Perspective products Thijs Spoor Chief Executive Officer 20+ years of expertise in biotechnology companies; public and private companies; oncology and nuclear pharmacy Jonathan HuntChief Financial Officer 20+ years of expertise in financial controls and public accounting for large and small companies across multiple industries Markus Puhlmann, MD MBAChief Medical Officer 20+ years of oncology drug development across all phases, experience coordinating multiple regulatory filings Frances Johnson, MDChief Innovation Officer 20+ years in clinical trials execution, managing academic research programs, founder and start-up of CareDx, Inc and Viewpoint MT Amos Hedt Chief Business Strategy Officer 20+ years of expertise in early-stage pharmaceutical and biotech drug development; 10+ years in radiopharmaceuticals Management TeamDeep Experience in Radiopharmaceuticals and Oncology Drug Development

Molecular imaging companion diagnostics enable visualization of the therapeutic target Enables the selection of patients who may best respond to therapy Perspective’s elementally matched isotopes are paired for imaging and therapy Radioligands can precisely deliver radiation directly to cancer cells reducing off-target effects Proven pillar of cancer treatment Perspective’s platform technology is optimized for greater efficacy and fewer side effects Radiopharmaceutical theranostic product development is highly-specialized and technical Greater expertise needed than for standard medicines potentially creating higher barriers to entry Perspective aims to develop patent-protected and best-in-class intellectual property Ability for both monotherapy and combination treatments Potential synergies with DNA damage response and immune checkpoint inhibitors Perspective’s targeted alpha therapy delivers potent and immunostimulatory radiation to tumor Modern medical isotopes enable radiopharmaceuticals to be administered outside of hospitals Treatments are easily-accessible globally with several hundred therapeutic locations in the U.S alone Perspective’s short half-life isotopes simplify patient administration and waste management Molecularly Targeted Radiation Optimized Patient Selection Monotherapy Activity andCombination Synergies Outpatient Friendly Unique BusinessOpportunity Radiopharmaceuticals are a Pillar of Oncology Treatment Unique Mechanism of Action Offers Pan-Cancer Opportunities

Targeting Peptide Engineered for cancer-specific receptors to ensure highly directed uptake Linker Selected to assist peptide binding and optimize clearance from blood and healthy tissues Isotope 203Pb for SPECT imaging Chelator Perspective’s proprietary platform technology enabling stable radiolabeling with Pb isotopes or 212Pb for alpha particle therapy Perspective’s Radiopharmaceutical Optimization ProcessUnique Mechanism of Action Offers Pan-Cancer Opportunities

1Company estimates and assumptions based on current literature and known physical constants Lead (212Pb) Iodine (131I) Lutetium (177Lu) Actinium (225Ac) Implication1 Emission Profile Alpha Beta Beta Alpha Potent Half Life 0.46 days 8 days 6.7 days 10 days High dose-rate Off Target Toxicity Risk Low Very high Low High Best Supply High High Low Low Abundant Cost of Production Low Low High High High margin With a much higher atomic mass, alpha (α) particles generate more energy and travel a shorter distance compared to beta (β) particles, making them more cytotoxic, while reducing their off-targeting effects on healthy tissue Alpha radiation causes direct lethal double-stranded DNA breaks, vs indirect single-stranded breaks in beta (β) radiation Cell death expected – NO resistance Greater therapeutic efficacy expected to improve outcomes with better safety Lead-212 (212Pb): The Optimal Therapeutic IsotopeAlpha Particles Provide Numerous Benefits Over Currently Used Beta Particle Radiotherapies

1”Pb-Specific Chelator”; 2Mirzadeh et al., Radiochimica Acta, 1993 Generic chelators have not been optimized for Pb isotopes, potentially compromising safety, efficacy and manufacturing efficiency Commercially Available Perspective’s Chelator Perspective’s Proprietary Chelator: Designed specifically for Pb isotopes Optimized for rapid renal clearance through neutralized formal charge Improves radiolabeling, receptor binding & internalization Generic chelators leak the 212Bi alpha-emitting daughter up to 36%2 Chelator Optimized for 212/203PbPerspective’s Enabling Technology for Pb-based Radiopharmaceuticals DOTA NET 2- TCMC NET 2+ PSC1 NET 0

Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of CancerIdentical Distribution of 203Pb and 212Pb for Imaging and Treatment, Respectively Unpublished data

Neuroendocrine Tumors: VMT-⍺-NET Targeting the somatostatin receptor to treat rare neuroendocrine-type cancers

Image Panel: SPECT scan of NETs patient imaged with [203Pb]VMT-𝛼-NET Initiated therapy (2022) investigator led study in India – data on 13 patients presented at SNMMI in June 2024 Fast Track Designation for first line therapy received October 2022 Therapeutic trial in PRRT naïve setting currently recruiting throughout the US US Phase 1 study in PRRT refractory patients recruiting at the University of Iowa VMT-⍺-NET will potentially expand into this population as well as PRRT naïve patients Targeting somatostatin receptor type 2 (SSTR2) for the imaging and treatment of neuroendocrine tumors with possible expansion into other SSTR2+ tumor types VMT-⍺-NET Development Status

Neuroendocrine tumors (NETs) Neuroendocrine cells are specialized cells that secrete hormones and other bioactive substances Neuroendocrine cells are found throughout the body Often grow in the pancreas or other areas of the gut, such as the stomach, small intestine, rectum, colon or appendix SSTR2 is expressed widely in various tumors Meningioma Pituitary adenomas Nasopharyngeal carcinoma Thyroid cancer Breast cancer Small cell lung cancers Merkel cell carcinoma Melanoma SSTR2 is an Attractive Target for Identifying and Treating TumorsExpressed Across Several Tumor Types

SSTR2 tumor model demonstrates superiority of VMT-𝛼-NET to generic compounds 8-fold improved tumor uptake with decreased kidney retention Key Takeaways Generic 203Pb-DOTATOC Proprietary 203Pb-VMT-α-NET Tumor Kidneys Potential Superiority of Perspective’s Platform Technology vs Generic CompoundsDecreased Off-Target Toxicity, Increased Tumor Uptake and Retention in Preclinical Studies Lee D, et al. Eur J Nucl Med Mol Imaging. 2024;51(4):1147-1162. doi:10.1007/s00259-023-06494-9

Drug Administered [212Pb]VMT-α-NET (1 x 120 µCi) Vehicle [212Pb]VMT-α-NET (4 x 30 µCi) [177Lu]DOTATATE (3 x 500 µCi) Standard of Care VMT-α-NET Shows Significant Improvement vs Standard of Care in Preclinical ModelsSuperior Clinical Activity with Single Dose or Multiple Administrations in AR42J SSTR2-Expressing Tumor Lee D, et al. Eur J Nucl Med Mol Imaging. 2024;51(4):1147-1162. doi:10.1007/s00259-023-06494-9

Tumors visible within 1 hour indicates rapid binding to SSTR2 target High intensity above background implies excellent therapeutic window Unbound drug in bladder within 1 hour for excretion Low renal retention due to neutral charge on proprietary Pb-specific chelator 21 hours Rapid Tumor Targeting and Renal Clearance 1 hour High Tumor Retention 203Pb SPECT Imaging Reveals Favorable VMT-α-NET Properties1 1Muller et al., Clin. Nucl. Med. 2023

Both 203Pb and 212Pb can be imaged directly using SPECT SPECT/CT shows very rapid tumor uptake and retention of [212Pb]VMT-α-NET After 24 hours more than 80% of alpha particles will be generated This high alpha dose rate is ideally matched to the biological clearance of the VMT-α-NET peptide 203Pb SPECT/CT Imaging1 Pt#001 212Pb SPECT/CT Imaging2 Pt#009 1.5 hrsSPECT/CT 22 hrsSPECT/CT 19.5 hrsSPECT/CT 2.5 hrsSPECT/CT 1Muller et al., Clin. Nucl. Med. 2023; 2Michler et al., EJNMMI 2023 212Pb SPECT/CT Imaging Confirms VMT-α-NET Tumor UptakeDiagnostic and Therapeutic Show Same Uptake and Retention Characteristics

Tumor Before Treatment Tumor After 1 Dose Significant Response After Single Dose of [212Pb]VMT-⍺-NET Metastatic NET Pancreas with Adrenal Crisis – Maximum Intensity Projection (MIP) 68Ga-DOTA-NOC PET images at base line and post 1st dose of [212Pb]VMT-α-NET MIP suggesting strong reduction of intensity (thoracic lesions) and decreasing tumor volume (Partial Response) Fortis Memorial research institute (FMRI), Gurugram, India

1 Serum Adrenocorticotropic Hormone (S.ACTH)1– 790 pg/ml S.ACTH – 96 pg/ml Tumor Before Treatment Tumor After 1 Dose Tumor After 3 Doses Significant Response After Single Dose, Almost Complete Response After 3 DosesMetastatic NET Pancreas with Adrenal Crisis

Current Status Patients with prior lines of therapy, late-stage, anatomically different NETs (mean age: 51 years; 6 females) 13 patients administered [212Pb]VMT-⍺-NET 6/13 patients continuing on therapy 2 patients completed all 6 treatments 45 total [212Pb] VMT-α-NET doses administered to date Response Interim Overall Response Rate (ORR) seen in 10/13 (76.9%) Partial Response Rate 8/13 (61.5%) Unconfirmed Partial Response 2/13 (15.4%) Treating Physician: Dr. Ishita B Sen Director & Head Dept. of Nuclear Med. & Molecular Imaging Fortis Memorial Research Institute, Gurgaon, India Safety 5 fatal adverse events have been reported so far Death from underlying disease/progressive disease (N=4), sudden cardiac arrest (n=1) (Non-Fatal) Myelodysplastic Syndrome (n=1) , no causal relationship found. Subject BCR-ABL1 gene positive. On Imatinib maintenance, remains well No other substantial high grade hematological toxicity Alopecia is moderate and transient and appears to be related to SSTR expression in the hair follicles. Dysphagia is moderate and transient, etiology uncertain Clinical Investigation of [212Pb]VMT-⍺-NET in Metastatic SSTR2 Positive PatientsResults as of May 31, 2024 for Ongoing Investigation in India Dr Ishita Sen, Fortis Memorial research institute (FMRI), Gurugram, India. Presented at SNMMI 2024

Dr Ishita Sen, Fortis Memorial research institute (FMRI), Gurugram, India. Presented at SNMMI 2024

1mTPI-2: Modified toxicity probability index https://clinicaltrials.gov/study/NCT05636618 Note: average administered activity from Indian investigator led research was 2.9 mCi per cycle Primary Objective: To determine the MTD/MFD of [212Pb]VMT-α-NET (RP2D) Imaging: FDA approved SSTR2 PET/CT Population: Unresectable or metastatic SSTR2-positive NETs PRRT naïve (“First line”) Therapeutic Dose: 2.5–10 mCi dose escalation with fixed dosing every 8 weeks for up to 4 cycles Estimated Time to Primary Completion: ~18 months Design Methodology: Bayesian mTPI2 based on iterative toxicity probability monitoring Dosimetry: To be assessed during screening for cohorts 1 & 2 using 5-7 mCi [203Pb]VMT-α-NET Escalation phase Expansion phase Expansion into non-NET indications (eg SCLC) also possible Recommended Phase 2 Dose Expansion Cohort [212Pb]VMT-⍺-NET RP2D mCi x 4 Recruitment Complete Cohort 1 [212Pb]VMT-⍺-NET n = 2   /   2.5 mCi x 4 Recruited Cohort 2 [212Pb]VMT-⍺-NET n = 7 / 5 mCi x 4 Cohort 3 [212Pb]VMT-⍺-NET n = 3 – 8 / 7.5 mCi x 4 Cohort 4 [212Pb]VMT-⍺-NET n = 3 – 8 / 10 mCi x 4 De-escalation possible for Cohort 2 – 4 including for intermediate doses Trial Design: [212Pb]VMT-α-NET mTPI-21 Phase 1/2a For Neuroendocrine Tumors Added slots: total of up to 47

Melanoma Program: VMT01/02 Using the melanocortin receptor MC1R to target melanoma for imaging and therapy

Image: Top panel - PET/CT cross section of a metastatic melanoma patient using FDG; middle panel - PET/CT of the same patient with VMT02; lower panel - SPECT/CT of same patient with VMT01 Targeting melanocortin 1 receptor (MC1R) which is over-expressed in melanoma Preclinical data shows synergistic effect with Immune Checkpoint Inhibitors Planning underway for VMT01/ICI combination in second line setting Phase 1 imaging study at Mayo Clinic Rochester indicates feasibility of patient selection using [203Pb]VMT01 and [68Ga]VMT02  US Therapeutic Dose Escalation Trial recruiting currently throughout the US Expected to Receive Orphan Drug Designation and Fast Track Application VMT01 Development Status

Advanced stages of disease occurs throughout the body requiring aggressive systemic treatment 1https://www.marketdataforecast.com/market-reports/melanoma-therapeutics-market, 2cancer.org, 3curemelanoma.org​ [212Pb]VMT01 target indication: MC1R-positive melanoma Projected market opportunity for melanoma of $8 billion+ in 20281 Significant unmet need in the U.S.: ~100K new diagnoses annually2 ~8,000 people die from melanoma every year2 Treatment depends on the stage of tumor Approaches may include surgery, radiation, chemotherapy and immunotherapy 5-year survival rate for metastatic melanoma is only 22.5%3 Skin (Primary) Brain Lymph nodes Lungs Liver Metastatic Melanoma

18F-FDG (Standard of Care) [68Ga]VMT02 Xiaowei Ma, M.D., Ph.D. Assoc. Prof. & Director Department of Nuclear Med. The Second Xiangya Hospital Central South University China Clinical Collaborator: Patient information: Male, Asian, 33 years old [68Ga]VMT02: 7 mCi injection, 45 min post-injection imaging [68Ga]VMT02 PET Imaging in Patient with MC1R Positive Metastatic MelanomaDiagnostic Peptide Demonstrates Similar Uptake to FDG in Tumors

Key Takeaways High response rates in multiple tested models >70% complete and durable response if combined with PD1 immunotherapy in a model highly resistant to checkpoint inhibitors3 Combination with immune checkpoint inhibitors induced synergistic anti-tumor effect 1Li et al., Mol. Pharm., 2019; 2Li et al., Cancers, 2021 3 Unpublished data - Statistical analysis was performed by Log-rank (Mantel-Cox): *p<0.05, **p<0.01, ns: non-significant Immunodeficient human melanoma xenograft model – BRAF-positive1 Single dose VMT01 + BRAFi vs. BRAFi alone 0 0 Percent Survival Continuous Zelboraf Days 80 60 40 20 10 20 30 40 50 60 70 80 90 100 Control BRAFi 212Pb 𝛼-therapy + BRAFi Percent Survival Days 0 100 Immunocompetent mouse B16:F10 melanoma model2 Single dose VMT01 + dual ICIs vs dual ICI: (anti-CTLA4 + anti-PD1) Dual ICIs 212Pb 𝛼-therapy 212Pb 𝛼-therapy + dual ICIs Control 0 10 20 30 40 50 60 70 80 80 60 40 20 [212Pb]VMT01 in Combination: Synergistic Responses in Preclinical Studies Single dose of VMT01 in combination significantly arrested melanoma tumor growth and extended survival 0 0 Percent Survival Days 80 60 40 20 10 20 30 40 50 60 100 Immunocompetent mouse B16:F10 melanoma model3 Single dose VMT01 + anti-PD-1 ICI generates 71% complete response rate Clinical Collaboration Agreement with Bristol-Myers Squibb signed for OPDIVO® (nivolumab) supply

De-escalation possible for Cohort 2 – 4 including for intermediate doses 1mTPI-2: Modified toxicity probability index https://clinicaltrials.gov/study/NCT05655312 Monotherapy Escalation phase n ≈ 32 Recruitment Complete Cohort 1 [212Pb]VMT01 n = 3 / 3 mCi x 3 Recruited Cohort 2 [212Pb]VMT01 n = 7 / 5 mCi x 3 Cohort 3 [212Pb]VMT01 n = 3 – 8 / 10 mCi x 3 Cohort 4 [212Pb]VMT01 n = 3 – 8 / 15 mCi x 3 Primary Objective: To determine the MTD/MFD of [212Pb]VMT01 (RP2D) Imaging: [203Pb]VMT01 SPEC/CT or [68Ga]VMT02 PET/CT Population: Enroll ~52 subjects Unresectable or metastatic MC1R-positive melanoma After 1L SOC Therapeutic Dose: 3 – 15 mCi dose escalation of [212Pb]VMT01 with fixed dosing every 8 weeks for up to 3 cycles Estimated Time to Primary Completion: ~18 months Design Methodology: Bayesian mTPI2 based on iterative toxicity probability monitoring Dosimetry: To be assessed using 15 - 25 mCi therapeutic surrogate [203Pb]VMT01 Trial Design: [212Pb]VMT01-T101 mTPI1 Phase 1/2a For Metastatic Melanoma COMBO Cohort 5 [212Pb]VMT01/PD-1 N = 2 – 8 @ 3 mCi COMBO Cohort 6 [212Pb]VMT01/PD-1 N = 2 – 8 @ 5 mCi COMBO Cohort 7 [212Pb]VMT01/PD-1 N = 2 – 8 @ TBD mCi Combination Escalation/ De-escalation phase Recommended Phase 2 Dose Expansion Cohort [212Pb]VMT01 n ≈ 20 RP2D mCi x 3 Phase I Amendment: [212Pb]VMT01 in Combination with Nivolumab – Sequential Design Primary Objective: To determine the MTD/MFD of [212Pb]VMT01 (RP2D) in combination with PD-1 inhibitor (nivolumab) Imaging: [203Pb]VMT01 SPEC/CT Population: Enroll ~52 subjects Unresectable or metastatic MC1R-positive melanoma  After 1L SOC Therapeutic Dose: 3 – 15 mCi dose escalation of [212Pb]VMT01 with fixed dosing every 8 weeks for up to 3 cycles Combination: Nivolumab 480 mg Q4W for up to 2 yrs Estimated Time to Primary Completion: ~18 months Design Methodology: Bayesian mTPI2 based on iterative toxicity probability monitoring Dosimetry: To be assessed using 15 - 25 mCi therapeutic surrogate [203Pb]VMT01

Pan Cancer Target: PSV359 Preclinical Efficacy and First in Human Images of Novel Peptide Targeting Fibroblast Activation Protein alpha (FAPa)

Fibroblast Activation Protein  is a Pan Cancer Target Kratochwil et al., JNM, 2019 FAP is primarily expressed on tumor stroma cells, but also on some cancer cells Tumor stroma cells do not typically express cancer-specific markers like SSTR2 or MC1R

1Kratochwil et al., JNM, 2019 Sarcoma Expression of FAP- on Tumor Cells Expression of FAP- on Tumor Stroma Cells Lung Cancer NETs Average SUVmax of 68Ga-FAPI PET/CT Across 28 Different Cancer Types Fibroblast Activation Protein  is a Pan Cancer Target1Multiple imaging products in development such as 68Ga-FAPi, but significant therapeutic opportunity remains

Compound 3-30 Compound 3-42 Compound 3-59 Fibroblast Activation Protein -targeted Novel Compound DevelopmentIn-house peptide synthesis and in vivo capability allows rapid iteration and optimization of novel compounds Phage display screening Phage display followed by affinity maturation Bioconjugate chemistry and further optimization In vitro and in vivo binding assays identified lead candidates1 1Perspective unpublished data

1Perspective unpublished data; 2Zboralski et al., EJNMMI, 2022 Preclinical [212Pb]PSV359 Targeted Alpha Therapy1 [212Pb]PSV359 Demonstrates Preclinical Efficacy in Human Fibrosarcoma ModelCompares favorably against other therapeutic products in development2 40-day results hFAP-HT1080 Fibrosarcoma Model – Expressing hFAP-a 90-day results Comparison against other FAP-targeted therapies in development indicates promise of [212Pb]PSV359 in preclinical setting

[203Pb]PSV359 SPECT/CT FIH Imaging of [203Pb]PSV359 in Different Types of Cancers Source: Unpublished data Patient 1 Chondroblastic Osteosarcoma [203Pb]PSV359 Lesion in head of left humerus 1 hr 4 hr 18 hr 4 hr 18 hr

Patient 2 Neuroendocrine Tumor Source: Unpublished data [203Pb]PSV359 [203Pb]PSV359 SPECT/CT Lesion in head of left humerus 4 hr 18 hr 1 hr 4 hr 18 hr

Patient 3 Lung Adenocarcinoma Source: Unpublished data Lytic lesion in sacrum Lytic lesion in thoracic vertebra [203Pb]PSV359 [203Pb]PSV359 SPECT/CT 1 hr 4 hr 18 hr

FAP: Potential Indications 1Unmet need defined as one- minus five-year survival rate (overall for heme, metastatic for solid). 2 Patient size calculated as annual incidence for heme, and larger of mortality and metastatic incidence for solid. 3Modified from EvaluatePharma® July 2020, Evaluate Ltd.; Surveillance, Epidemiology, and End Results (SEER) Program High Unmet need1 Low Patient size,2 thousands 1 ALL 19 Cervical 2 AML 20 Glioma 3 Bladder 21 Glioblastoma 16 SCLC 32 CRC 17 TNBC 33 HCC 18 Uterine 34 NSCLC-Other 35 Pancreatic Major opportunities Niche 4 CLL 22 Soft tissue 5 CML 23 T cell 6 DLBCL 24 Thyroid 8 FL 25 Alk 9 GIST 26 EGFR 10 Head and neck 27 HER2+ 11 HL 28 HR+ 12 MDS 29 Myeloma 13 Melanoma 30 Prostate 14 NHL-Other 31 RCC 7 Esophageal Established markets 15 Ovarian Massive unmet need 2024 Potential Market ~$190B3 Market size, 2019 40 30 20 10 FAP: Potential Indications (expressed in 90%+ of epithelial cancers) Fibroblast Activated Protein  is a Pan Cancer Target with Significant Market PotentialTumor types with large patient populations and high unmet need

FAP- is a pan-cancer target that is highly expressed in many cancers Perspective’s in-house discovery team has developed an optimized peptide with potential best-in-class characteristics as demonstrated in preclinical models First in human clinical SPECT/CT imaging suggests the tumor targeting and retention of the PSV359 compound is excellent, while clearing from normal organs rapidly and completely The FAP- PSV359 program is a significant addition to Perspective’s clinical pipeline of targeted alpha therapeutic assets Summary – PSV359 FAP- ProgramPotential to be a best-in-class pan-cancer targeted alpha particle therapeutic [203Pb]PSV359 SPECT/CT1 Fortis Hospital, Ishita Sen MBBS, unpublished data (Patient 1, osteosarcoma)

Prostate Cancer Program: PSV401 A differentiated PSMA-targeted radiohybrid molecule for dual PET imaging and targeted alpha therapy

Prostate Cancer Program: PSV40XA differentiated PSMA-targeted radiohybrid molecule for dual PET imaging and targeted alpha therapy 1Johnson et al., RPT Interest Group June 7 2023 https://rrp.cancer.gov/working_groups/AlphaPET-RPT_Int_group_lecture.pdf Technology licensed from Mayo Clinic January 2024 IND-enabling studies underway First in human data expected in 2024 Has shown promise in reduction of salivary gland uptake in preclinical models of prostate cancer1 Combines two chelators with single targeting ligand to provide identical distribution of imaging and therapeutic agents PSMA is a clinically and commercially validated target for radioligand therapy Targeting ligand 64Cu 212Pb Therapeutic Diagnostic Linker Different Chelators Prostate SpecificMembraneAntigen (PSMA)

Higher tumor accumulation/retention Significantly lower salivary gland uptake and retention Significantly lower kidney accumulation and retention Higher therapeutic window and reducing the potential for xerostomia that limits current PSMA-targeted prostate cancer radiopharmaceutical therapies PSV40X: Improved Preclinical Metrics for a Superior Therapeutic Window in Prostate CancerPSV404 (designated NSN24901 by Mayo Clinic) shows promise in preclinical setting Comparison of Uptake of [68Ga]PSMA-11 and [64Cu]PSV404 (“NSN24901”) in Tumor, Kidney and Salivary Gland of LNCaP Tumor Athymic Nude Mice

Pre-Targeting Platform The Next Generation of Targeted Alpha Particle Radiopharmaceuticals

Pre-Targeting Platform BackgroundRelies on the different kinetics of large proteins and small molecules and a multi-step process 1 Administer cold modified monoclonal antibody or targeting protein 2 After several days, mAb will have accumulated on tumor and cleared from blood 3 Administer radiolabeled ligand 4 Ligand binds specifically to mAb and clears rapidly from circulation Radioligand on tumor Radioligand clears circulation rapidly Ligand binds only to modified mAb

Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics The Path to Commercial Supply

Naturally occurring in mining waste Also produced in industrial nuclear processes Can be made on demand if needed Isotope Source All other therapeutic isotopes require capital-intensive infrastructure manufacturing processes (irradiation) Isotope Purification VMT-𝛼-GEN enables shipping of isotope and purification of 212Pb in one package VMT-𝛼-GEN 212Pb generator technology scales for commercial production Extremely pure isotope allows straight forward manufacturing process 10.5 hr half life of 212Pb allows for robust regional distribution of finished radiopharmaceuticals Parent isotope Thorium-228 can be stored (2 yr half-life) 212Pb purified from 228Th or 224Ra source in simple separation step Product Manufacturing 212Pb is Plentiful, Storable, Scalable & Suitable for Distributed LogisticsThe supply chain is lower-risk and more robust than other therapeutic isotopes

Plentiful Supply: Naturally occurring, or produced as a waste product Chemical Separation: Allows for Ra-based generators of 212Pb 228Th Thorium 1.9 y 224Ra Radium 3.6 d 212Pb Lead 10.6 h 212Bi Bismuth 61 m Chemical Separation from 224Ra: Isotope used for manufacturing finished product High dose-rate alpha-emitting therapeutic isotope Multiple global suppliers including natural decay 2 year half-life allows stockpiling Half-life allows global distribution Weekly delivery of 224Ra enables daily 212Pb 3.6 day half-life allows local stockpiling Regional finished product manufacture Leverages existing networks for logistics 212Pb acts as in vivo “nanogenerator” of alphas Perspective’s chelator retains 212Bi in drug Isotope Decay Chain Dictates Supply, Purification, Manufacturing & LogisticsNaturally Occurring Isotope Decay – No Irradiation Processes Required

212Pb Isotope Purification Without Just-in-time IrradiationSimple chemical separation technology of natural decay products de-risks supply chain

5.7” 11” VMT-𝛼-GEN Extensive feedstock from nuclear and mining waste material Long-term supply contract secured with US DOE On demand daily doses Auto-regenerates overnight ~1 week shelf life Small, Elegant 212Pb Isotope Generator Integrated lead shielded containment Simple inlet and outlet ports Radioactive feedstock for nearly 300 generators fits in a small vial 212Pb Supply via Reusable Desktop Isotope Generator

Commercial supply will require the use of an isotope production system of larger scale than the current 224Ra/212Pb generators The current isotope separation process remains highly scalable with larger activity levels Regional CDMOs will have capabilities to expand capacity as needed as more 212Pb products come on-line Current Process Scaled Commercial Process Generator manufacturedand shippedto CDMO Generator eluted for 212Pb Isotope Largegeneratorsited in-houseat CDMO Generator eluted for 212Pb Logistics Isotope Synthesis & Dispensing CDMO Sites Generator Manufacturer CDMO with in-house 212Pb Generator Sites Radio-synthesis Module Dispensing Delivery Administration Scalable Manufacturing and Distribution LogisticsPerspective’s plan to flexibly scale manufacturing to commercial levels (100,000+ doses per year)

228Th Thorium 1.9 y 224Ra Radium 3.6 d 212Pb Lead 10.6 h 212Bi Bismuth 61 m 228Th 224Ra 224Ra 224Ra 224Ra 224Ra 224Ra 212Pb 212Pb 212Pb 212Pb 212Pb Central continental supply Eluted weekly for 224Ra Distributed continentally Eluted daily for 212Pb Daily manufacture of finished doses Leverages existing networks for logistics 212Pb acts as in vivo “nanogenerator” of alphas 212Pb 212Bi Isotope Decay Chain Dictates Supply, Purification, Manufacturing & LogisticsNaturally Occurring Isotope Decay – No Irradiation Processes Required

2014: 78 2024: 101 Infrastructure Modeling: Commercial History of PET Pharmacy Network DevelopmentNuclear medicine capability filled in to meet demand as clinical adoption of ultra short half-life PET agents widened PET Pharmacies1 1 Company estimates There were 40+ million diagnostic nuclear medicine procedures performed in the US in in 2022 Multiple networks exist in a competitive environment of 100+ GMP PET radiopharmacies Distribution logistics are mature and well-developed Many of these diagnostic products have much shorter half-lives than 212Pb 2004: 41

Location Radius 11 hr – 400 miles Coralville, IA 51 m Somerset, NJ 75 m Los Angeles, CA 46 m Austin, TX 32 m Atlanta, GA 57 m Orlando, FL 25 m Top 6 sites cover nearly 300 million people within a one half-life (11 hr) delivery radius1 Products can also be driven further or flown as necessary Proposed or existing manufacturing facility Circles represent distribution radii for facilities currently producing or sites anticipated for future manufacturing Regional Manufacturing Allows Commercialization of 212Pb-labeled Finished Products The “network effect” ensures reliable supply for intermediate half-life therapeutics Delivery radius of existing CATX manufacturing facilities 1 Company estimates

2 Issued Patents (Expiry in 2037, with potential PTE) Composition of matter and method of use on melanoma targeting peptides with Pb-specific chelator   1 Allowed AU Patent Application (Expiry in 2037) Composition of matter and method of use on melanoma targeting peptides with Pb-specific chelator 28 pending patent applications (including 5 PCT and 1 provisional) Composition of matter and method of use on: Radiometal separation technology Chelators SSTR2, MC1R, FAP, and PSMA targeting radiopharmaceuticals Pre-targeting technology platform Perspective-owned/Exclusively-licensed IP IP Portfolio covers all aspects of radiopharmaceutical value chain Potential for Orphan Drug Designation Potential for U.S. FDA Priority Review Voucher: VMT-𝛼-NET is a candidate for pediatric neuroblastoma indication Strong Intellectual Property Portfolio

Appendix

Targeting cancer from the inside out We are developing game-changing Precision Medicine Therapeutics which harness the power of targeted Alpha-Particle Radiotherapies that make an impactful difference for cancer patients and the clinicians who treat them. Our Mission

Who We Are Perspective Therapeutics (NYSE:CATX) is a clinical stage precision medicine company, debuting as a public company in 2023. With a broad pipeline and two prioritized lead programs in clinic, we are disrupting traditional radiation therapy treatment for cancer though developing a new class of image guided alpha-particle radiotherapies treatments for the most challenging cancers. With an initial focus on neuroendocrine tumors (NETs) and metastatic melanoma, we have a robust discovery platform to advance our pipeline into the clinic further. Perspective’s personalized theranostic approach arms physicians with companion imaging diagnostics, capturing personalized information about a patient’s cancer in the process which can then be used to guide precise radiation therapy, killing cancers from the inside out. Perspective’s core technology hinges on alpha (α) particle radiation which deliver large amounts of radioactive energy very specifically to tumors, irreparably damaging DNA and reliably killing the targeted tumor cells. We believe the use of alpha-particles provides numerous benefits over currently used beta-particle radiotherapies. Alpha-particles generate more energy and travel a shorter distance compared to beta-particles, making them more cytotoxic, while reducing their effects on healthy tissue.

1Li et al., Cancers, Jul 22;13(15), 2021 α-particles are >7,000-fold greater in atomic mass More Powerful Effects Than Approved β Therapy Higher atomic mass Lethal double-stranded DNA breaks DNA repair mechanisms overwhelmed Precision Delivery ProvidesTargeted Cell Destruction Deposit energy over 3-5 cell diameters vs. beta particles (up to 200 cells) Evidence for antitumor response alone or in combination with immunotherapies Consistent with “Abscopal effect” observed with external beam radiation therapy Anti-Tumor ImmuneResponse1 𝜶-Particles Have Superior Tumor Killing Properties vs. β-Particles 𝜶 β γ

Beta range (up to 200 cell diameters) Alpha particle range (up to 3 cell diameters) The destructive energy of an alpha particle is deposited within several cell diameters. A beta particle spreads its lower energy over a longer range Tumor Cells 10mm 𝛼 β ✚- - -✚ - - ✚ ✚-✚ - - ✚ 1mm - - - ✚ ✚ ✚ - - - ✚ ✚ - Normal Tissue ✚ - Cell 0.1mm - - Healthy tissue Tumor Lead-212 (212Pb): The Optimal Therapeutic IsotopeGreater Therapeutic Energy Expected to Improve Outcome with Better Safety Profile

Ideal agreement between imaging and therapeutic compounds 203Pb and 212Pb matched pair Readily available isotope Generator produced Ideal chelator Proprietary chelator carries 0 net charge Rapid clearance from blood Conjugation to small peptides High tumor retention @24 hours High and sustained binding Short t-½ gives rapid effect while minimizing environmental impact Low hospital and patient impact for radiation safety No unsafe daughter isotopes Decays to cold Pb Solutions: 203/212Pb & Perspective Chelator Ideal Theranostic Requirements Lead (Pb): The Ideal Theranostic Isotope

Blood clearance: rapid Tumor accumulation: rapid Time Injected Dose Ensures efficacy Peptide Kinetics mAb Kinetics Blood clearance: extended Tumor accumulation: extended Time Injected Dose Potential for toxicity mAb Size: 150 kDa 10 nanometers Peptide Size: 1.5 kDa 10 nanometers Monoclonal antibodies Peptides Kinetics Tumor penetration: Low Clearance: Hepatobiliary (liver) Biological ½ Life Long Target affinity High Accumulation time: Extended Stability Questionable Production Manufacturing: Complex biological CoGs: High Kinetics Tumor penetration: High Clearance: Renal (kidneys) Biological ½ Life Short Target affinity High Accumulation time: Rapid Stability Excellent Production Manufacturing: Synthetic CoGs: Very low Peptides are Ideal Ligands for Radiopharmaceutical Therapy

1cancer.net; ​; 2www.futuremarketinsights.com/reports/neuroendocrine-carcinoma-market;3LUTATHERA PI; 4Strosberg et al (2021); 5Navalkissoor et al (2019) Projected to be $2.9 billion+ in 20292 Existing radiopharmaceutical treatment LUTATHERA® (Novartis) has an overall response rate (ORR) of only 13–17%, and no overall survival (OS) benefit3 Treatment depends on the type of tumor. Some approaches may include surgery, radiation, and chemotherapy Broad acknowledgment that targeted alpha therapies are needed to improve care5 NETTER-1 Study: Final overall survival4  ~12K new diagnoses annually in the US1 ~175,000+ people are living with this diagnosis in the US1 Significant unmet need: Market Opportunity VMT-𝛼-NET is Developed to Address the Unmet Need in NETsCurrent Standard of Care limited to subset of NETs patients

T0 Post Final Purification  Dose Vial 225Ac 225Ac  221Fr  217At  213Po  213Bi ß “Free” Radiometals: Labeled 4 hours. T4 4 h post Radiolabeling 221Fr+ 217At- 213Bi3+ 213Po2+ 225Ac Ac-225 Decay and Daughter Ingrowth 1 kBq 225Ac starting dose size. Hours Post Purification 0 2 3 4 5 6 1 4x more unlabeled daughter activity in about 4 hrs Isotope: Decay chain – Product implicationsPost final radiolabeling and purification, alpha and beta emitting daughters of 225Ac build up fast

α α ꞵ α OH Potential for Off-Target Toxicity 221Fr Francium 5 Min 217Rn Radon 0.5 ms 213Bi Bismuth 46 m 209Pb Lead 3.3 h 213Po Polonium 4.3 µs 209TI Thallium 2 m α α α α α β β Isotope Supply Production 221Ra Radium 28 s 217At Astatine 32 ms 205Tl Thallium stable 209Bi Bismuth 2×1019 y β β α α α β Therapy 225Ac Actinium 10 d α 221Fr 217At 213Bi 213Po 225Ac Target Organs Liver Kidneys Alpha-particle emission imparts sufficient “recoil” energy to break chemical bonds 225Ac Isotope Decay Chain and Potential for Off-Target Toxicity α β α α

Therapy 228Th Thorium 1.9 y 224Ra Radium 3.6 d 220Rn Radon 1 m 216Po Polonium 0.1 s 212Bi Bismuth 61 m 208Tl Thallium 3 m 212Po Polonium 0.1 µs 208Pb Lead Stable 212Pb Lead 10.6 h α α α α α α β β β Isotope Supply Production α β 212Pb 212Bi Perspective’s proprietary chelator retains 98% of 212Bi after transition in drug formulation Generic chelators leak the 212Bi alpha-emitting daughter up to 36%1 1Mirzadeh et al., Radiochimica Acta, 1993 Where the drug goes = where the alpha particle is deposited 212Pb Isotope Decay Chain and Importance of the Pb-Specific Chelator

212Pb Hits Tumors Hard and Fast and Disappears212Pb is a “high dose rate” alpha emitter with a short half life – energy is deposited rapidly to tumor and then gone Comparative alpha Particle Decay Over Time1 Comparative alpha decays 0 ~80% of total 212Pb/212Bi alphas delivered to tumor within 24 hrs Hours Post administration 12 24 36 48 60 72 “Activity” is measured in decays per second, so depends on isotope half-life 212Pb will likely be administered at 20 times the 225Ac activity 1 Representative activity administrations only, based on clinical projections – company estimates ~6% of total 225Ac alphas within 24 hrs 225Ac is administered in smaller activities due to its 10 day half-life and the total alphas decays from its daughters 225Ac on tumor: It takes 23 days to deliver 80% of alphas Unbound alphas – potential for toxicity Most drugs stay bound to tumor for only a limited time – this directly affects the amount of radiation that can be delivered The effectiveness of longer-lived isotopes therefore diminishes over time the alphas are also removed from the tumor Delivering alphas faster whilst drug and isotope tumor retention is high enables a better therapeutic index: greater efficacy with less off target toxicity

Isotope: Decay chain – Biological ImplicationsIsotope selection drives potential for off target toxicities 225Ac has potential for off target toxicity Decay products circulate and continue to emit radition 212Pb decay is limited to tumor Toxicity to liver and kidneys Recoil breaks chemical bonds

Clinical Trial Principal InvestigatorsRenowned Experts in Radiotherapy Development Geoffrey B. Johnson MD, PhDChair, Division of Nuclear Medicine Chair, PET/MR R&D Associate Professor Departments of Radiology and Immunology Mayo Clinic – Rochester, MN Vikas Prasad MD Professor of Radiology Associate Professor Radiology, Division of Nuclear Medicine Washington University in St Louis – St Louis, MO Yusuf Menda MD Professor of Radiology Chair, Division of Nuclear Medicine Project Leader Neuroendocrine Tumor SPORE University of Iowa – Iowa City, IA Zachary Morris, MD, PhD Professor of Radiation Oncology Associate Professor, Department of Human Oncology The University of Wisconsin – Madison, WI

Appendix: VMT-⍺-NET Additional Material and Data from Clinical Investigation at Fortis Memorial Research Institute, Gurgaon, India

NET Trials 177Lu-DOTATATE Study NETTER-1 (1) (2) RCT; randomized 2:1 N = 229 Dose Level (administered) 4 x Q8W  200 mCi  Patient Population SSTR2+, GEP-NETs Prior PRRT 0% Median time from dx 3.8 years Performance Status Karnofsky Performance Scale Median was 90 Histology Well differentiated G1 (66%), G2 (35%) PFS Median 28.4 vs 8.5 months (3) ORR (CR/PR) 13% (1%/12%) vs. 4% (0%/4%) AEs (>20%) Nausea, vomiting, fatigue, diarrhea, abdominal pain, multiple laboratory abnormalities Grade 3+ (>10%) Lymphopenia (44%), GGT↑ (20%) Other notes 5 Lu-177 treated  patients withdrew due to renal-related events (1) US prescribing information; (2) DOI: 10.1056/NEJMoa1607427; (3) NANETS 2021; (4) DOI: 10.1016/S0140-6736(24)00701-3; (5) ASCO 2024; (6) ASCO 2024; (7) SNMMI 2024. No head-to-head studies between the products have been conducted. Given the different study designs and methods, cross-trial comparisons cannot be made. The information on this slide is not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the investigational agents will receive regulatory approval or become commercially available for the uses being investigated. VMT-α-NET Investigator led research (7) N=13 4 x Q8W 67 µCi/kg  median 2.9 mCi SSTR2+ GEP-NETs, B-NETs, MTCs 62% N/A ECOG 0 (38%), 1( 31%), 2 (31%) Well differentiated G1 (15%), G2 (85%) Median 16.4 months 62% (0%/62%) confirmed >10 events: alopecia, anemia, fatigue, nausea Anemia (2 events) Transient dysphagia resolved without intervention 177Lu-DOTATATE 212Pb-DOTAMTATE 225Ac-DOTATATE NETTER-2 (4) RCT; randomized 2:1 N = 226 Phase I/II (5) Single arm N=44 ACTION-1 Phase Ib/III (6) Phase Ib: Single arm N=17 4 x Q8W  200 mCi  4 x Q8W 67 µCi/kg  4.7 mCi/70 kg 4 x Q8W 3.2 uCi/kg  0.23 mCi/70 kg SSTR2+, GEP-NETs SSTR2+, GEP-NETs  SSTR2+, GEP-NETS 0% 0% 100% 1.9 months 5 years 5 years Karnofsky Performance Scale 83% at 90-100 N/A ECOG 0 (59%), 1 (41%) Well differentiated G2 (73%), G3 (27%) Well differentiated G1 (18%), G2 (68%), G3 (7%) Well differentiated G1 (47%), G2 (53%) Median 22.8 vs 8.5 months 74.3% at 24 months NE (95% CI: 12 months, NE) 43% (5%/38%) vs. 9% (0%/9%) 56% 29.4% confirmed 41.2% (6%/35%) w/ unconfirmed Nausea, diarrhea Alopecia, nausea, fatigue, appetite↓, diarrhea, dysphagia, lymphocyte count↓, abdominal pain, vomiting, weight↓, blood glucose↑ Nausea, fatigue, weight↓, hyperglycemia, abdominal pain, constipation, vomiting, multiple laboratory abnormalities TEAE: 35% TEAE: 52% Lymphocyte count↓ (25%) TEAE: 53% Anemia (18%), lymphocyte count↓ (18%), creatinine clearance↓ (12%) Nephrotoxicities 13 (8.8%) vs. (2.0%) Dysphagia treated with Botox injection

MIP image Before Treatment MIP image After 2nd Treatment Liver Metastases after treatment with two doses Liver Metastases before treatment Significant Tumor Response After Two DosesPatient 3: Metastatic NET Pancreas with Liver Metastases

Tumor Before Treatment Tumor After Treatment Reduction in Size of Necrotic Masses After 2 Doses Patient 5: Pancreatic NET

Hemoglobin Levels Platelet Counts Serum Creatinine Total Leukocyte Count Favorable Safety and Tolerability Profile Four Months Post-Treatment (5 Patients)

Pre-Therapy Post-Therapy 79 year-male Metastatic Medullary Carcinoma thyroid Disease progression of TKI’s Received total 3 doses of [212Pb]VMT-α-NET therapy at an interval of 8 weeks (Cumulative dose 9.6 mCi) Shows Partial response for disease till date. Developed MDS on routine blood investigations Found positive for BCR-ABL gene Patient Profile No causal relationship could be established Serious Adverse Event in Patient 2Myelodysplastic syndrome (MDS) Unrelated to Study Drug

25 year-male Metastatic NET-pancreas Long-standing disease (>6 years duration) Heavily pre-treated with Inj. Sandostatin and 4 cycles of 177Lu-DOTATATE along with CAPTEM regimen Received 1 dose of [212Pb]VMT-α-NET therapy (3.5 mCi) Acute Cardiac Event (Possible Carcinoid Heart Syndrome) Significant Tumor Burden - Possible Disease Progression Significant tumor burden Patient Profile No causal relationship could be established Serious Adverse Event in Patient 6Acute Cardiac Event Unrelated to Study Drug

Appendix: Preclinical Programs: Pre-targeting Platform

Peptide and peptide-like small molecules Rely on fast clearance from the body to reduce radiation dose to non-target tissues Typically clear through the kidneys Sometimes tumor retention is an issue Less suitable for long-lived isotopes Examples: LUTATHERA®, PLUVICTO®, VMT01, VMT-α-NET etc Blood clearance: rapid Tumor accumulation: Rapid but may not be sustained Time Injected Dose Peptide & Small Molecule Kinetics1 Pre-targeting Rationale: Current Radiopharmaceutical State of the ArtPeptide-based radiopharmaceuticals are the most successful commercial radioligand products We believe peptides are the ideal targeting vectors for high dose-rate isotopes such as 212Pb, as the biological and radiation half-lives are matched 1Company Estimates

FDA has approved over 100 mAbs: 9 of the top 20 therapeutic products worldwide with more than $75 billion in sales (2021)1 ADCs are commercially successful (current market size approx $10 billion2) but some safety issues with Blackbox warnings3 Success of mAbs as vectors to target radiation has been limited (BEXXAR®, Zevalin®)4 Long circulation times increase off-target radiation toxicity to marrow and healthy organs compared to peptides or small molecules5 Tumor accumulation can be very high and retention long Very long list of targets for mAbs available Blood clearance: Extended Tumor accumulation: slow but high and durable Time Injected Dose mAb Kinetics6 Pre-targeting Rationale: mAbs Have Significant Role in Cancer TherapyAntibody Drug Conjugates (ADCs) are a successful high-growth product class but mAbs are not ideal radiopharmaceuticals Antibodies and antibody fragments have high and specific tumor uptake but clear slowly so are not ideal radiopharmaceuticals 1Mullard, Nat Rev Drug Discovery 2021; 2www.marketsandmarkets.com/Market-Reports/antibody-drug-conjugates-market-122857391.html; 3Nguyen et al, Cancers, 2023; 4www.nytimes.com/2007/07/14/health/14lymphoma.html; 5Rondon et al, Cancers, 2021; 6Company Estimates

Unpublished data, undisclosed target 48 hours post- injection 120 hours post- injection Observations Question? Specificity of mAbs: [203Pb]mAb SPECT Imaging Preclinical Example Is it possible to exploit the tumor targeting and uptake of mAbs, but retain the rapid clearance properties of peptides and small molecules? Precise tumor targeting Accumulation over days Residual radiation clears High-resolution image

Biokinetic Properties of mAbs are Ideal for Accumulation on TargetRepresentative imaging across longer time frame demonstrates clearance and uptake kinetics 1O'Donoghue et al. J Nucl Med 2018 Long circulation time with little tumor uptake for the first 24 h High accumulation of mAb onto tumor with clearance from blood pool Patient with HER2 positive esophagogastric adenocarcinoma metastatic to liver, imaged with [89Zr]trastuzumab1

Pre-Targeting Platform BackgroundRelies on the different kinetics of large proteins and small molecules and a multi-step process 1 Administer cold modified monoclonal antibody or targeting protein 2 After several days, mAb will have accumulated on tumor and cleared from blood 3 Administer radiolabeled ligand 4 Ligand binds specifically to mAb and clears rapidly from circulation Radioligand on tumor Radioligand clears circulation rapidly Ligand binds only to modified mAb

1Bodet-Milin et al., JNM 2021 Immuno-PET/CT with anti-CEA BsmAb and 68Ga-IMP288 peptide showing pathological lesions with heterogeneous SUVmax ranging from 3.0 to 20.1 Maximum-intensity-projection (MIP) image (A) showed several pathological lesions On the fusion axial images, arrows located mediastinal nodes (B), subcutaneous lesions (C), and bone metastasis (D) Compelling Proof of Concept for pretargeting, but this system lacks broad “modularity” Promise of Pre-Targeted Approach – Clinical Data68Ga-IMP288 – Images ≥ 24 hours following Anti-CEA Bispecific mAb1

Jallinoja et al. J Nucl Med. 2021. Clinically Evaluated (Phase I / II) Preclinically Evaluated only Not Modular Immunogenic Four platforms reported prior to 2021 3 of 4 have been promising preclinically All face specific hurdles for widespread clinical use: Lack of "modularity“ Immunogenicity Poor tumor uptake Stability Common hurdle = use of clearing agents Current state of the art B. Streptavidin - Biotin D. Click Chemistry Unstable A. Bispecific Antibody – Hapten (eg SADA) C. Oligonucleotide Hybridization OR + + + + State of the Art in Pre-Targeting for RadiopharmaceuticalsReview of current state of the art technology platforms

Jallnoya et al., JNM 2021 First synthesized 1905 (Behrend, Germany) Structure described analytically 1981 Named after the pumpkin family Cucurbitacea Cucurbit[7]uril (CB7) modifiedantibody (mAb) OR HOST An ideal pretargeting agent: High in vivo stability Modular Non-toxic Non-immunogenic No need for a clearing agent Perspective Pre-Targeting Platform: Host - Guest ChemistryAfter exhaustive review of State of the Art, Perspective chose CB7 (Host) - Adamantane (Guest) System

Unpublished data Perspective Pre-Targeting Platform: Host - Guest Chemistry and in vivo ExperimentSynthesized the Guest as an adamantane-PEG3-PSC (Perspective’s proprietary chelator) 6-day lag time demonstrates stability of the CB7 Terrific Tumor:Normal ratios Very low kidney/liver retention High tumor targeting Blood clearance of the radioligand a little slow System optimization underway First in vivo Experiment: Observations

Unpublished data Perspective Pre-Targeting Platform: Host - Guest Chemistry in vivo Imaging ExperimentRepresentative images of ligand during optimization process 4 hours post guest 8 hours post guest 24 hours post guest MIP coronal MIP coronal MIP coronal Host is a mAb targeting Carcinoembryonic Antigen (CEA) Guest is an adamantane-PEG3-NOTA labeled with 64Cu 72 h lag time post Host administration

Bosi et al., EJ Cancer 2023 54 distinct cell surface targets Li et al., Cancers, 2022 371 target membrane protein-coding genes Subbiah, Curr. Probl. Cancer, 2021 13 ADC targets – compared to radiopharmaceuticals Vast number of mAbs that are humanized and have been in human clinical trials Many have failed as Antibody Drug Conjugates and unmodified ligand may be available for licensing These mAbs bind in general with high affinity and specificity to their tumor targets Opportunity to significantly increase potency of these molecules Many mAbs with Clinical Data Perspective Pre-Targeting Platform: Significant Opportunity to Expand into “ADC” spaceVast number of mAb targets and ligands available to exploit Expansive Range of Targets Available Perspective’s pre-targeting platform has the potential to transform a large range of existing molecules and targets into “radio-ADCs” with superior efficacy and reduced toxicity

Appendix: Prostate Cancer Program – PSV40X

Typical Theranostic Approach : One Molecule, One Chelator, One IsotopeSeparate But Chemically Identical Molecules Labeled with Either 203Pb or 212Pb for Imaging and Treatment, Respectively Note:One chelatorOne isotope Unpublished data

Enables the same molecular entity to treat with lead-212 (212Pb) and image by PET with Copper-64 (64Cu) Co-labeled with non-radioactive Pb provides identical biodistribution, allowing reliable dosimetry using 64Cu Technology Licensed from Mayo Clinic January 20241 IND-enabling studies underway First in Human data expected in 2024 Two chelators on one targeting ligand Each can be labeled with stable or radioactive atoms PSV401 DoubLET1,2: One Molecule, Two Chelators, Four Possible Isotopes One Molecule Labelled with Two Elements at Once, with Isotope Selection Determining Diagnostic or Therapeutic Targeting ligand 64/67/natCu 203/212/natPb Therapeutic or Diagnostic Diagnostic or Therapeutic Linker Different Chelators Prostate Specific Membrane Antigen (PSMA) 1PSV401 is also known in the literature/Mayo documentation as NSN24901 or AlphaPET-PSMA01. 2. DoubLET trademark and patent pending

1www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html​; 2www.precedenceresearch.com/prostate-cancer-market; 3PLUVICTO PI; 4Novartis AG Q3 2023 Earnings Call Transcript 5Sartor et al (2021); 6www.urotoday.com/clinical-trials/from-the-editor/142064-targeted-alpha-therapy-for-prostate-cancer-the-next-generation-of-alpha-emitting-radiopharmaceuticals.html; 7Langbein et al (2022) Projected to be $27.5 billion+ in 20322 Existing radiopharmaceutical treatment PLUVICTO® (Novartis) has an overall response rate (ORR) of 30%, and an overall survival (OS) benefit of 4 months3 PLUVICTO® expected to reach sales ($1B plus) in only 2nd year on market4 Treatment depends on the stage of tumor. Typical approaches include surgery, radiation, chemotherapy and androgen-deprivation therapy Broad acknowledgment that targeted alpha therapies are needed to improve care6 Salivary gland toxicity (xerostomia) is a common adverse side effect of PSMA targeted RPT (≅ 40%) and negatively impacts quality of life7 VISION Study: Overall survival5  ~288K new diagnoses annually in the US1 ~3.3M+ men living with this diagnosis in the US1 ~35K deaths annually in the US1 Significant Unmet Need: Market Opportunity: PSV401 Has Potential to be “Best-In-Class” Prostate Cancer Targeted Alpha TherapyCurrent Standard of Care with Beta-Based Radiopharmaceutical Therapy (RPT) Still Requires Improvement

PSMA+ LNCaP tumor model suggests [64Cu]PSV401 targets tumor rapidly – suitable for diagnostic or treatment monitoring Imaging product also indicates effective renal clearance and no other dose-limiting organs, essential for targeted alpha particle therapy Key Takeaways PSV401: Preclinical 64Cu PET Imaging Data Showing Tumor UptakeRapid Tumor Uptake and Effective Renal Clearance with Radioactive Imaging Isotope 1 1Johnson et al., RPT Interest Group June 7 2023 https://rrp.cancer.gov/working_groups/AlphaPET-RPT_Int_group_lecture.pdf

PSV401: Preclinical Comparison to Industry Standard1[64Cu]PSV401 Compares Favorably to FDA-Approved Imaging Agent [68Ga]PSMA-11 (ILLUCCIX®, Telix)2 [64Cu]PSV401 [68Ga]PSMA-11 1LNCaP tumor athymic nude mice 2Johnson et al., RPT Interest Group June 7 2023 https://rrp.cancer.gov/working_groups/AlphaPET-RPT_Int_group_lecture.pdf Note absence of salivary gland (SG) uptake with PSV401

PSV401: Preclinical Comparison to Industry Standard[64Cu]PSV401 Significantly1 Improved Uptake/Clearance Compared to [68Ga]PSMA-112 Tumor Retention 1* indicates p < 0.05 [64Cu]PSV401 vs [68Ga]PSMA-11 (all data sets as indicated) 2Johnson et al., RPT Interest Group June 7 2023 https://rrp.cancer.gov/working_groups/AlphaPET-RPT_Int_group_lecture.pdf; 3SUV = Standardized Uptake Variable [68Ga]PSMA-11 [64Cu]PSV401 Kidney Retention Salivary Gland Retention [68Ga]PSMA-11 [64Cu]PSV401 [68Ga]PSMA-11 [64Cu]PSV401 Time (min) Time (min) Time (min) PSMA+ Tumor SUV3 Kidney SUV2 Salivary Gland SUV2 Key Differentiation to Competitors Higher tumor accumulation/retention Significantly lower salivary gland uptake and retention Significantly lower kidney accumulation and retention Larger therapeutic window (greater efficacy and reduced toxicity)

All imaging performed with [64Cu]PSV401 microPET Treatment of PSMA+ prostate cancer xenograft with [212Pb]PSV401 reduced tumor size 38% in 3 days and complete response after 9 days Additional preclinical work underway Preclinical [212Pb]PSV401 TherapyPreliminary [212Pb]PSV401 Data Shows Potential to Effectively Kill Tumors 1 1Johnson et al., RPT Interest Group June 7 2023 https://rrp.cancer.gov/working_groups/AlphaPET-RPT_Int_group_lecture.pdf 18 Days Post [212Pb]PSV401 Dose 2 Days Prior to [212Pb]PSV401

Appendix: Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics

Plentiful Supply: Naturally occurring, or produced as a waste product Chemical Separation: Allows for Ra-based generators of 212Pb 228Th Thorium 1.9 y 224Ra Radium 3.6 d 212Pb Lead 10.6 h 212Bi Bismuth 61 m Chemical Separation from 224Ra: Isotope used for manufacturing finished product High dose-rate alpha-emitting therapeutic isotope Multiple global suppliers including natural decay 2 year half-life allows stockpiling Half-life allows global distribution Weekly delivery of 224Ra enables daily 212Pb 3.6 day half-life allows local storage Regional finished product manufacturing Leverages existing networks for logistics 212Pb acts as in vivo “nanogenerator” of alphas Perspective’s chelator retains 212Bi in drug Isotope Decay Chain Dictates Supply, Purification, Manufacturing & LogisticsNaturally Occurring Isotope Decay – No Irradiation Processes Required

228Th Thorium 1.9 y 224Ra Radium 3.6 d 212Pb Lead 10.6 h 212Bi Bismuth 61 m Perspective currently has a 10 year supply agreement with US Department of Energy Produced as a waste by-product from isotope 223Ra (Xofigo) manufacture Irradiation to produce very large quantities (100s of Ci) in a high-flux reactor can be performed every 6-12 months in a single batch, or as needed 2-year half-life allows stockpiling and de-risks the supply chain 8+ suppliers identified across the globe 224Ra grows in naturally (without irradiation) from 228Th decay 228Th half-life of 1.9 years allows long term storage and extraction of daughter 224Ra Parent Isotope SourceKey Isotopes for Supply: 228Th and 224Ra

Flexible and Scalable Isotope Supply224Ra enables Regional Manufacturing Hubs 228Th Thorium 1.9 y 224Ra Radium 3.6 d 212Pb Lead 10.6 h 212Bi Bismuth 61 m 212Pb grows in naturally (without irradiation) from 224Ra decay 224Ra half-life of 3.6 days allows weekly shipments to regional manufacturing sites Perspective’s proprietary VMT-𝛼-GEN enables shipping of isotope and purification of 212Pb in one package, simplifying supply VMT-𝛼-GEN generator technology scales for commercial production Extremely pure isotope allows straight-forward production process Regional manufacturing sites will not require licenses for any long-lived isotopes, reducing costs and waste concerns Other 212Pb production processes are possible Perspective’s proprietary VMT-𝛼-GEN enables shipping of isotope and purification of 212Pb in one package, simplifying supply

Naturally occurring in mining waste Also produced in industrial nuclear processes Can be made on demand if needed Isotope Source All other therapeutic isotopes require capital-intensive infrastructure manufacturing processes (irradiation) Isotope Purification VMT-𝛼-GEN enables shipping of isotope and purification of 212Pb in one package VMT-𝛼-GEN 212Pb generator technology scales for commercial production Extremely pure isotope allows straight forward manufacturing process 10.5 hr half life of 212Pb allows for robust regional distribution of finished radiopharmaceuticals Parent isotope Thorium-228 can be stored (2 yr half-life) 212Pb purified from 228Th or 224Ra source in simple separation step Product Manufacturing 212Pb is Plentiful, Storable, Scalable & Suitable for Distributed LogisticsThe supply chain is lower-risk and more robust than other therapeutic isotopes

Parent Isotope Source Storage of thorium-228 (half-life of 1.9 years) allows for “on-demand” purification of Ra-224 and Pb-212 Multiple purification/production methods for Th-228 with different starting materials and processes, including Ra-228 generators (half-life 5.7 years) Ra-224 (half-life 3.6 days) allows for continental shipping of material to network of finished product manufacturing sites (CDMOs) A weekly supply of Ra-224 can be purified daily to produce batches of Pb-212 Key Isotopes for Supply: Th-228 and Ra-224 Commercial Production and Distribution of 212Pb-labeled Finished Radiopharmaceuticals – March 2023 Ra-224 grows in naturally (without irradiation) from a Th-228 “source” Pb-212 grows in naturally (without irradiation) from a Ra-224 “source”

228Th Replenishment 4 Ci per year 100,0001 Finished Doses per year 212Pb Dose Modeling from Parent IsotopeReplenishable 228Th stockpile ensures supply of commercial quantities of 212Pb for finished dose manufacture1 Perspective Stockpile 10 Ci 228Th Thorium 1.9 year 212Pb Lead 10.6 h Purification Manufacturing Hospital 1 Approximations based on company estimates

Thorium-228 is available as a natural isotope but is also produced as a waste product from the nuclear fuel cycle, and as a result of production of therapeutic isotope Ra-223 (marketed as Xofigo, Bayer) Both Ac-227 (the parent isotope of Ra-223) and Th-228 are created when DOE’s ORNL irradiates radium-226 in the High Flux Isotope Reactor.1 The DOE therefore has 10s of curies of Th-228 available in a highly purified form Perspective Therapeutics estimates that such current quantities would suffice for approximately 150,000+ patient doses per year Perspective has a long-term supply agreement with the DOE for supply of Th-228 Large quantities of precursor Th-228 available The availability of parent isotope in large quantities significantly de-risks supply of Pb-212 as a therapeutic isotope. In addition, it provides methodological flexibility for Pb-212, as there are many processes available for large-scale purification. Michael Schultz, PhD Co-Founder and CSO 17+ years industry and research experience in radiopharmaceuticals Produced as a waste product, 10s of Ci available Pb-212 sourced as an emanation product in some systems Allows for Ra-based generators of Pb-212 Commercial Production and Distribution of 212Pb-labeled Finished Radiopharmaceuticals – March 2023 Natural decay, no input needed Parent Isotope Supply 1. https://www.ornl.gov/news/thorium-228-supply-ripe-research-medical-applications

Pb-212 Isotope Purification Multiple purification paths to Pb-212 available Similar in size to Ga-68 generators Useful for preclinical R&D and clinical trials Nimble, portable supply available for either local or regional production Typically chromatography column based Using Ra-224 as parent Shelf life approx. 1-2 weeks 1-2 doses per batch per day Examples: DOE VMT-α-GEN “Desktop” generators Useful for clinical trials & limited commercial production Non-portable, fixed location within hot cell in local production facility Gas-phase separation of the Rn-220 Shelf life approx. 1 year 1-3 doses per batch per day Examples: Advancell, others Hot cell-sized generators For commercial production Non-portable, fixed location within hot cell in regional production facility Either chromatography or gas-phase separation using Th-228 source Permanent installation, topped up with Th-228 approx every 3 to 6 mo Questions about scalability and licensing Examples: Multiple In development Small scale Medium scale Commercial scale The production of Pb-212 is inherently scalable to demand, flexible due to different purification schemes and cost-effective due to existing isotope availably. This contrasts with other alpha-emitting isotopes which require large infrastructure to produce and purify. Commercial Production and Distribution of 212Pb-labeled Finished Radiopharmaceuticals – March 2023

5.7” 11” VMT-𝛼-GEN Extensive feedstock from nuclear and mining waste material Long-term supply contract secured with US DOE On demand daily doses Auto-regenerates overnight ~1 week shelf life Small, Elegant 212Pb Isotope Generator Integrated lead shielded containment Simple inlet and outlet ports Radioactive feedstock for nearly 300 generators fits in a small vial 212Pb Supply via Reusable Desktop Isotope Generator

Commercial supply will require the use of an isotope production system of larger scale than the current 224Ra/212Pb generators The current isotope separation process remains highly scalable with larger activity levels Regional CDMOs will have capabilities to expand capacity as needed as more 212Pb products come on-line Current Process Scaled Commercial Process Generator manufacturedand shippedto CDMO Generator eluted for 212Pb Isotope Largegeneratorsited in-houseat CDMO Generator eluted for 212Pb Logistics Isotope Synthesis & Dispensing CDMO Sites Generator Manufacturer CDMO with in-house 212Pb Generator Sites Radio-synthesis Module Dispensing Delivery Administration Scalable Manufacturing and Distribution LogisticsPerspective’s plan to flexibly scale manufacturing to commercial levels (100,000+ doses per year)

Single centralized manufacturing facility Suitable for longer half-life isotopes (eg 177Lu, 131I, 225Ac, 67Cu) Allows for national/international production Shipping of finished product typically requires air and road transport Single point of failure (eg Novartis’ PLUVICTO® production issues) National network of manufacturing facilities Suitable for shorter half-life isotopes (eg 212Pb, 211At) Requires multiple manufacturing sites for regional finished product Shipping of finished product typically road transport No single point of failure Allows for flexibility and redundancy, improving reliability of supply Redundancy fills in to meet demand vs Centralized vs Distributed Network ProductionNetworked production is more reliable and utilizes existing logistics for distributed supply 1 The national network of manufacturing facilities is based on current company plans

Isotope: Availability and Scalability at Clinical Development Stages Isotope Production methods Large, centralized capital-intensive infrastructure such as reactors, cyclotrons, LINACs etc. Suitable for longer half-life isotopes (eg. Lu-177, I-131, Ac-225, Cu-64/67, Pb-203 etc.) Allows for national/international production, shipping of finished product Somewhat vulnerable as redundancy can be expensive Large capital investment required (subsidized by government currently) Generator-based supply that can be deployed locally or regionally (Portable or in-house permanent installation) Suitable for shorter half-life isotopes with appropriate decay schemes (eg. Tc-99m, Pb-212, Ga-68) Requires multiple manufacturing sites across a network & local/regional finished product Allows for flexibility and redundancy, improving reliability of patient dose supply Vs. 7.75” 3.5” Can be scaled for multi-dose manufacture at regional CDMOs with permanent in-house Pb-212 generator: Perspective’s approach for commercialization or

Isotope and Finished Product Landscape: Commercial Supply Centralized Isotope and Manufacturing - Competitors Pb-212-labeled Commercial Perspective Products Parent Isotope Source Isotope Production Method Purification of Isotope Isotope Shipping Finished Product Manufacturing Logistics Summary Functions are assigned and employees are trained based on function. Team/organization responsible for QA duties. Operations performed in defined areas. Air quality defined for production areas i.e. ISO 6, airlocks. Initials and signature of person performing work required. Initials and signature of 2nd person for verification required. Th-228 available in very plentiful, pure supply Allows for stockpiling of precursor parent isotope No need for irradiation – Th-228 decays to Ra-224 and Pb-212 Occurs on-site prior to finished product within existing CDMO facilities (commercial) Parent isotope at site already (commercial) Distributed network of scalable regional manufacturing sites Distributed by regional facilities Short supply chains, vertical integration of activities, simple processing, greater redundancy, less capital intensive, more environmentally friendly, scalable to demand Commercial Production and Distribution of 212Pb-labeled Finished Radiopharmaceuticals – March 2023 Lu-177: Ytterbium-176 is expensive. Limited supply from Russian sources. Purification is a cumbersome process Ac-225: Limited access to parent supplies such as Ra-226, U-233 Multiple production methods available, some lead to contaminants Typically requires dedicated nuclear reactors or large accelerators Extremely large hot cells required for initial separation Can be off site at third parties in dedicated facilities Isotope frequently shipped to site for finished product manufacture Typically centralized at one large site Distributed nationally Long supply chains, higher 3rd Party risk, complex processing, less redundancy, more labor and capital intensive, less environmentally friendly, not scalable to demand Cost High-mid vs Low High-mid vs Low High vs Mid Similar (1 $$$ site vs multiple $) Mid vs Low Similar Higher up front for centralized approach, but similar costs post finished product